| Factor | Score | Distribution | Value | Avg | Rank |
|---|---|---|---|---|---|
Valuation | 52 | 22.3x | 17.8x | Around median | |
Growth | 51 | 9.8% | 7.1% | Around median | |
Quality | 72 | 6.9% | 4.5% | Top tier | |
Safety | 69 | 2.1x | 2.6x | Top tier | |
Capital Return | 52 | 3.13% | 2.12% | Around median | |
Momentum | 56 | -3.8% | 2.9% | Around median | |
Sentiment | 62 | 17 | 3 | Around median |
Estimates — analyst targets and a simplified DCF, not investment advice.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.
Medtronic plc operates in medical technology through a broad portfolio spanning cardiovascular therapies, neuroscience technologies, surgical instruments, monitoring and acute care, and diabetes. Among its largest sources of operating revenue are the Surgical business, with more than $6 billion annually, and Cardiac Rhythm Management, with more than $5.5 billion, while Cardiac Ablation Solutions revenue exceeded $2 billion during the twelve months ended in the first quarter of fiscal 2027. The company generates revenue from the sale of devices and capital systems, such as Affera, Hugo, and Stealth AXiS, and from products used in medical procedures, such as catheters, implants, and LigaSure and V-Loc instruments, enabling recurring revenue growth as the installed base expands.
In the first quarter of fiscal 2027 ended July 31, 2026, revenue was $9.8 billion, representing both organic and reported growth of 13.7%, while net income according to EDGAR filings was approximately $1.5 billion and earnings per share were $1.14. The company recorded gross profit of $6.3 billion, equivalent to a calculated gross margin of approximately 64.3%, while reported adjusted gross margin was 65.2%, up 10 basis points, and adjusted operating profit was $2.3 billion at a margin of 23.7%. It also reported adjusted earnings per share of $1.45, exceeding the midpoint of management guidance and market expectations by $0.06.
Growth was broad-based across the portfolio in the first quarter of fiscal 2027: Cardiovascular revenue increased 19%, Neuroscience 9%, Medical Surgical 10%, and Diabetes 15%. Within these segments, Cardiac Ablation Solutions grew 88% globally, Cardiac Rhythm Management 15%, Cranial & Spinal Technologies 13%, and Surgical 9%. For annual comparison, Medtronic generated fiscal 2026 revenue of $36.4 billion, gross profit of $23.6 billion, and net income of $4.8 billion, compared with revenue of $37.5 billion and net income of $5.2 billion during the twelve-month period ended within fiscal 2027.
The average analyst price target is $99.4 within a wide range of $83 to $119, compared with the stock's 52-week range of $73.31 to $106.33; accordingly, the average target is below the top of the 52-week range, while the highest target exceeds that peak. The analyst consensus is “Buy,” and based on the reference price used in the September 1, 2026 news report, the forward price-to-earnings ratio at the midpoint of adjusted earnings per share guidance of $5.97 was approximately 15.2 times, compared with a historical forward multiple of 24.2 times provided by the source; this decline reflects a combination of stock revaluation despite improving growth, while risks remain from slowing growth after the impact of the additional week and from mix and investment pressures on margins.
Figures in the text are as of 2026-09-04; the live price is shown at the top of the page.
Medtronic's revenue in the first quarter of fiscal 2027 ended July 31, 2026 was approximately $9.8 billion, with organic and reported growth of 13.7%, while adjusted earnings per share reached $1.45. Cardiovascular led growth with a 19% increase, including 88% growth in Cardiac Ablation Solutions and 15% growth in Cardiac Rhythm Management. Neuroscience also grew 9%, Medical Surgical 10%, and Diabetes 15%. However, the additional fiscal week contributed approximately $570 million, or 670 basis points, to reported organic growth, so underlying growth was calculated to be closer to 7%.
Cardiac Ablation Solutions grew 88% globally and 139% in the United States in the first quarter of fiscal 2027, and its revenue exceeded $2 billion over the twelve-month period. Sphere-9's share in the United States increased by 9 points, while the U.S. Affera installed base expanded by more than 35% sequentially after increasing 40% in the previous quarter. 75% of the installed base was in high-volume centers, and management says some centers with one or two systems are requesting additional systems. In August 2026, CE marking expanded Sphere-9's use in Europe to include the treatment of ventricular arrhythmias, while enrollment began in the pivotal U.S. trial for this use.
Automated analysis for informational purposes only — not investment advice.
Medtronic intends to complete the separation of MiniMed before the end of fiscal 2027, with Diabetes remaining included in full-year fiscal guidance until then. The Diabetes business grew 15% in the first quarter of fiscal 2027, but management describes it as lower-margin and more consumer-oriented than the rest of the portfolio. Management estimates that removing it from the consolidated financial statements will reduce Medtronic's growth by approximately 20 basis points but increase gross margin by approximately 50 basis points and operating margin by approximately 100 basis points. The transaction aims to give Medtronic and MiniMed independent capital-allocation strategies suited to their different financial profiles.
The company expects the Hugo system to surpass 50,000 procedures and reach 250 installed units by the end of fiscal 2027, with its procedure volumes growing at more than twice the market rate. Touch Surgery is used in more than 1,500 operating rooms worldwide, while Touch Surgery Aide provides 300 times greater computing power to support artificial intelligence applications in the operating room. Medtronic invested approximately $700 million in Cornerstone and entered into an agreement to distribute the Sentire Surgical System in selected markets outside the United States, with the financial impact of the distribution agreement expected to begin in fiscal 2028. Management describes Sentire as a complement to Hugo that gives international customers broader options, not a replacement for it.
On September 1, 2026, the company raised its fiscal 2027 organic revenue growth guidance to 7.25%–7.75%, an increase of 50 basis points from the previous range. It also raised adjusted earnings per share guidance to $5.94–$6.00 and expects operating profit growth of approximately 10% and operating margin expansion of about 50 basis points. For the second quarter of fiscal 2027, it expects organic growth of approximately 6% and adjusted earnings per share of between $1.32 and $1.34. The guidance includes foreign exchange headwinds of between $50 million and $150 million for the full fiscal year and does not assume additional tariff refunds during the remainder of the year.
Insider activity during the three months ended with the latest transaction on July 8, 2026 included three sales and no purchases, with a net sale value of approximately $594,897. These data represent a weak trading signal on their own because insider sales may be prearranged, and the provided context does not explain the reasons for the transactions or whether they were part of scheduled plans. Therefore, these transactions alone are insufficient to assess the business outlook, particularly because the company raised its fiscal 2027 revenue growth and earnings per share guidance on September 1, 2026. The more direct operating indicators remain organic revenue growth adjusted for the impact of the additional week, Affera's expansion, the margin trajectory, and execution of the MiniMed separation. Satisfaction
